Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIV4 vs IIV4 Immunogenicity and Safety in South Korea
NCT05144945Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinin in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Influenza Vaccine Antibodies at Day 29, Geometric Mean Fold-rise for Influenza Vaccine Antibodies at Day 29 and 8 more. Started Dec 2021; status: completed.
02
Drugs
influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05144945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144945.